MannKind's stock has surged 73%, driven by its 9% royalty stake in United Therapeutics' Tyvaso DPI, which excels in the PAH market. In Q2 2024, MannKind's revenues rose 49% year-over-year to $72 ...

MannKind (MNKD), which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider. This biopharmaceutical company has seen a nice streak of beating ...

MannKind (MNKD) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MNKD broke through the 20-day moving average, which suggests a ...

MNKD opened at $6.73 on Thursday. MannKind has a twelve month low of $3.17 and a twelve month high of $6.92. The company has a fifty day moving average of $6.03 and a 200-day moving average of $5. ...

AQR Capital Management LLC increased its holdings in MannKind Co. (NASDAQ:MNKD – Free Report) by 8.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC.

MannKind (MNKD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Year-to-Date Revenue: $139 million, a 55% increase over the prior year period. MannKind Corp (NASDAQ:MNKD) reported record revenue of $72 million for the second quarter of 2024, marking a 49% increase ...

Warning! GuruFocus has detected 8 Warning Signs with MNKD. MannKind Corp (NASDAQ:MNKD) reported record revenue of $72 million for the second quarter of 2024, marking a 49% increase compared to the ...

MannKind (MNKD) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MNKD broke through the 20-day moving average, which suggests a short ...